Legend Biotech Corp

Annual Trend FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Cash flows from operating activities:
Net Income ($446.3m)
($518.3m) -16.12%
($177.0m) +65.85%
($296.8m) -67.68%
($236.5m) +20.32%
Net Income From Continuing Operations ($445.7m) ($520.2m) ($158.1m) ($282.6m) ($236.5m)
Purchase Of Financial Assets Measured At Fair Value Through Profit Or Loss Classified As Investing Activities $149.2m $0
Fair value gains on financial assets measured at fair value change through profit or loss ($89k) ($474k) ($47k) $0 ($593k) ($663k) $0 $0
Purchase of financial assets measured at fair value through profit or loss ($314.8m) ($22.7m) ($50.0m) ($285.0m) $0 ($149.2m) $0
Cash received from withdrawal of financial assets measured at fair value through profit or loss $320.9m $22.7m $50.1m $100.0m $185.0m $149.2m $0
Profit or Loss ($133.0m) ($303.5m) ($403.6m) ($446.3m) ($518.3m) ($177.0m) ($296.8m)
Other Adjustments To Reconcile Profit Loss $1.3m
Depreciation of property, plant and equipment $845k $4.0m $8.2m $11.0m $10.2m $10.7m $10.7m $9.4m $39.4m
Depreciation of right-of-use assets $823k $1.2m $1.5m $1.5m $5.7m $7.8m $10.7m $19.5m $39.4m
Amortization Cash Flow $1.4m $2.5m $1.9m $1.9m
Amortization Of Intangibles $1.4m $2.5m $1.9m $1.9m $908k
Depreciation $15.9m $18.5m $21.4m $28.9m $39.4m
Equity-settled share-based compensation expense $704k $1.3m $4.8m $20.2m $34.3m $47.7m $68.9m $64.6m
Loss on asset impairment $0 $4.4m $0
Asset Impairment Charge $0 $0 $4.4m $0 $0
Cash flows from (used in) operations before changes in working capital ($12.7m) ($128.9m) ($211.8m) ($340.5m) ($402.5m) ($368.1m) ($198.2m) ($40.7m)
Change In Working Capital $181.0m ($72.7m) $18.4m ($93.1m) ($94.4m)
(Increase)/decrease in trade receivables $207.6m ($3.8m) ($45.0m) $24.6m $50.3m ($99.0m) $93.8m ($5.7m)
Increase in prepayments, other receivables and other assets ($2.5m) ($3.9m) $3.4m ($3.0m) ($50.6m) ($8.7m) ($61.7m) ($126.8m)
Change In Receivables $50.3m ($99.0m) $93.8m ($5.7m) ($200k)
Changes In Account Receivables $50.3m ($99.0m) $93.8m ($5.7m) ($200k)
Provision for inventory reserve $0 $5.3m $3.6m $12.7m ($3.0m)
Increase in collaboration inventories ($1.1m) ($22k) ($643k) $51k ($8.6m) ($12.7m) ($17.2m) ($4.5m)
Change In Inventory ($13.9m) ($12.7m) ($17.2m) ($4.5m) ($600k)
Increase/(decrease) in trade payables $3.2m $2.0m ($4.3m) $1.8m $25.9m ($12.7m) $14.1m $44.4m
Increase/(decrease) in other payables and accruals $18.3m $31.7m $20.2m $142.1m $165.9m ($38.8m) $45.7m $36.1m
Other assets and liabilities, net $600k ($4.8m) $3.4m
Change In Other Current Assets ($1.2m) $3.7m $753k ($4.6m) ($3.7m)
Change In Other Current Liabilities ($158k) ($163k) ($176k) ($55k) $1k
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment ($21.0m) ($38.6m) ($45.7m) ($43.9m) ($20.9m) ($20.1m) ($14.1m) ($28.6m)
Net Other Investing Changes ($14.7m) ($97.9m) ($54.4m) ($38.8m) ($41.8m)
Proceeds From Borrowings Classified As Financing Activities $2.9m
Repayments Of Borrowings Classified As Financing Activities $2.9m
Net Issuance Payments Of Debt ($2.6m) ($3.8m) ($4.0m) ($3.6m) ($4.1m)
Net Long Term Debt Issuance ($2.6m) ($3.8m) ($4.0m) ($3.6m) ($4.1m)
Long Term Debt Payments ($2.6m) ($3.8m) ($4.0m) ($3.6m) ($4.1m)
Repayment Of Debt ($2.6m) ($3.8m) ($4.0m) ($3.6m) ($4.1m)
Issuance Of Capital Stock $377.6m $583.7m $0 $0 $0
Common Stock Issuance $377.6m $583.7m $0 $0 $0
Net cash (used in) provided by financing activities $2.5m
$14.7m +486.41%
$618.9m +4119.82%
$626.7m +1.26%
$378.0m -39.68%
$791.5m +109.40%
$5.7m -99.28%
($300k) -105.27%
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS $207.9m ($127.1m) $371.7m $233.2m $491.7m ($991.0m) $615.2m
Beginning Cash Position $688.9m $786.0m $1.3b $286.7m $441.7m
Cash and cash equivalents at beginning of year $2.1m $210.2m $83.4m $455.7m $688.9m $786.0m $1.3b $286.7m $901.9m $441.7m
Effect of foreign exchange rate changes, net $124k $249k $620k $34k ($2.5m) $682k ($2.1m) $6.1m
Effect Of Exchange Rate Changes ($2.5m) $700k ($2.1m) $6.1m $3.5m
Additional Supplementary Disclosures
Additional Supplementary Disclosures
Additional Financial Items
Adjustments For Current Tax Of Prior Period ($6.6m) $658k $1k $0
Adjustments For Decrease Increase In Trade Account Receivable ($3.8m) ($45.0m) $24.6m $50.3m ($99.0m) $93.8m ($5.7m)
Adjustments For Finance Costs $82k $223k $4.2m $900k $10.8m $21.8m $21.6m $21.4m
Adjustments For Finance Income $4.6m $2.9m $971k $8.2m $54.5m $61.2m $40.1m
Adjustments For Unrealised Foreign Exchange Losses Gains ($250k) ($66k) $4.9m $9.2m $28.2m ($109.3m) $168.8m
Payments Of Lease Liabilities Classified As Financing Activities $5.1m $2.6m $1.4m $2.6m $3.8m $4.0m $3.6m
Purchase Of Intangible Assets Classified As Investing Activities $534k $4.0m $3.2m $1.3m $2.6m $0 $0
Loss before tax ($1.6m) ($130.4m) ($307.6m) ($386.2m) ($445.7m) ($520.1m) ($158.1m) ($282.6m)
Finance income ($6.2m) ($4.6m) ($2.9m) ($971k) ($8.2m) ($54.5m) ($61.2m) ($40.1m)
Fair value loss of warrant liability $6.2m ($20.9m) $85.8m $0 $0
Foreign currency exchange loss/(gain), net ($7.2m) ($250k) ($66k) $4.9m $9.2m $28.2m ($109.3m) $168.8m
Other, net $1.6m $1.5m $1.3m
(Decrease)/increase in contract liabilities, net $0 $100.0m ($49.7m) ($40.0m)
Interest income received $1.8m $9.0m $3.4m $652k $5.6m $47.3m $37.3m $52.0m
Income tax received $7.4m $557k $3.7m $976k $0 $0
Purchase of intangible assets ($63k) ($534k) ($4.0m) ($3.2m) ($1.3m) ($2.6m) $0 $0
Payment to collaborator for collaboration assets ($98.8m) ($54.9m) ($38.8m)
Purchase of equity instruments $0 $0 ($5.0m)
Cash receipts of investment income $47k $0 $1.3m $8.8m $2.5m $0
Addition in time deposits ($75.6m) ($50.0m) ($298.1m) ($370.0m) ($4.9b) ($2.6b) ($4.5b)
Decrease in time deposits $75.6m $180.0m $483.6m $4.9b $1.8b $5.3b
Decrease in pledged deposits $255k $0 $0 $105k $907k $516k $0
Proceeds from issuance of ordinary shares for institutional investors, net of issuance cost $0 $0 $234.4m $0 $0
Proceeds from issuance of ordinary shares for follow on public offering, net of issuance costs $0 $323.4m $377.6m $349.3m $0 $0
Proceeds from exercise of warrant by warrant holder, net of issuance cost $0 $0 $199.7m $0 $0
Proceeds from exercise of share options $1.5m $4.6m $2.9m $11.8m $9.7m $3.3m
Principal portion of lease payments ($219k) ($5.1m) ($2.6m) ($1.4m) ($2.6m) ($3.8m) ($4.0m) ($3.6m)
Cash and bank balances $210.4m $159.2m $506.1m $858.6m $841.3m $1.3b $1.1b $948.6m
Less: Pledged deposits $255k $256k $384k $1.4m $1.3m $357k $70k $0
Time deposits $75.6m $50.0m $168.2m $54.0m $34.7m $840.3m $46.7m
Cash Flow From Continuing Financing Activities $378.0m $791.4m $5.7m ($300k) ($2.1m)
Cash Flow From Continuing Investing Activities ($77.1m) $92.9m ($850.6m) $709.6m $285.0m
Change In Account Payable $72.4m ($50.2m) $14.1m $44.4m $16.8m
Change In Other Working Capital ($15k) $100.6m ($54.5m) ($36.6m) ($35.2m)
Change In Payable $191.7m ($52.9m) $58.0m $80.5m $16.8m
Change In Prepaid Assets ($50.6m) ($8.7m) ($61.7m) ($126.8m) ($85.2m)
Changes In Cash $99.6m $491.0m ($988.9m) $609.1m $201.2m
End Cash Position $786.0m $1.3b $286.7m $901.9m $642.9m
Financing Cash Flow $378.0m
$791.4m +109.38%
$5.7m -99.28%
($300k) -105.26%
($2.1m) -600.00%
Free Cash Flow ($223.6m) ($416.0m) ($158.1m) ($128.8m) ($115.8m)
Gain Loss On Investment Securities $6.2m ($20.9m) $85.8m
Gain Loss On Sale Of PPE $974k $481k $226k $2k $250k
Interest Received CFO $5.6m $47.3m $37.3m $52.0m $52.0m
Investing Cash Flow ($77.1m) $92.9m ($850.6m) $709.6m $285.0m
Net Foreign Currency Exchange Gain Loss $9.2m $28.2m ($109.3m) $168.8m $119.5m
Net Intangibles Purchase And Sale ($1.3m) ($2.6m) $0 $0 $0
Net PPE Purchase And Sale ($20.9m) ($20.1m) ($14.1m) ($28.6m) ($34.1m)
Net Preferred Stock Issuance $0 $0 $0
Operating Gains Losses ($11.3m) $114.0m ($109.3m) $168.8m $119.5m
Other Non Cash Items $8.5m ($31.1m) ($38.1m) ($17.4m)
Proceeds From Stock Option Exercised $2.9m $211.5m $9.7m $3.3m $2.0m
Provisionand Write Offof Assets $5.3m $3.6m $12.7m ($3.0m) ($5.3m)
Purchase Of Intangibles ($1.3m) ($2.6m) $0 $0 $0
Purchase Of PPE $45.7m $42.2m ($20.9m) ($20.1m) ($14.1m) ($28.6m) ($34.1m)
Sale Of PPE $4k $0 $0
Stock Based Compensation $34.3m $47.7m $68.9m $64.6m $68.0m
Unrealized Gain Loss On Investment Securities ($593k) ($700k) $0 $0 $0
Net Investment Purchase And Sale ($40.1m) $213.5m ($782.1m) $777.0m $360.9m
Purchase Of Investment ($655.0m) ($4.9b) ($2.7b) ($4.5b) ($4.8b)
Sale Of Investment $614.9m $5.1b $1.9b $5.3b $5.1b
Cash and cash equivalents as stated in the statement of financial position $210.2m $83.4m $455.7m $688.9m $786.0m $1.3b $286.7m $901.9m
Cash and cash equivalents as stated in the statement of cash flows $210.2m $83.4m $455.7m $688.9m $786.0m $1.3b $286.7m $901.9m
Change In Cash Supplemental As Reported $99.6m $491.7m ($991.0m) $615.2m
Interest Paid CFO ($142k) ($527k) ($1.4m) ($1.8m) ($2.2m)
Income Taxes Paid Refund Classified As Operating Activities ($15.4m) ($7.4m) ($557k) ($3.7m) ($976k) $0 $0

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.